home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

245 rows where filing_period = "third_quarter", filing_year = 2016 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 245 ✖

filing_year 1

  • 2016 · 245 ✖

filing_period 1

  • third_quarter · 245 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1873352 AMERICAN COLLEGE OF CLINICAL PHARMACY 59c67d5f-2758-4630-859e-d3cbbb2897fa Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2016 third_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128875 0 0 2016-10-06T10:09:33.290000-04:00
1873519 NELSON MULLINS RILEY & SCARBOROUGH 5893ed93-4ec5-40d7-8f93-c9c4b850a0ec Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2016 third_quarter PHA Issues related to 340B Drug Pricing Progam HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-10-06T13:47:33.257000-04:00
1873521 NELSON MULLINS RILEY & SCARBOROUGH 3d846365-f6cc-4f66-bc28-653f5aa39c72 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2016 third_quarter PHA Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-10-06T13:48:34.693000-04:00
1873600 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 98ad3ed9-a90f-42d7-b675-ef726476488a Q3 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 1967 AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 2016 third_quarter PHA H.R.2298-Medicare Patient Safety and Drug Abuse Prevention Act S.1913-Stopping Medication Abuse and Protecting Seniors Act of 2015 HOUSE OF REPRESENTATIVES,SENATE   512329 0 0 2016-10-06T22:34:59.390000-04:00
1873715 WAXMAN STRATEGIES e8b7173c-d16a-4ed0-8b6a-68b3bdbc6edc Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2016 third_quarter PHA Laws and regulations affecting the 340B Drug Discount Program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),White House Office 18750   0 0 2016-10-07T11:38:35.293000-04:00
1873731 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 881551d5-98bf-43cc-96d2-5f8ecf036978 Q3 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2016 third_quarter PHA In-office compounding; outsourcing facilities; Drug Quality and Security Act Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)     0 0 2016-10-07T11:44:47.280000-04:00
1873810 NELSON MULLINS RILEY & SCARBOROUGH 773d1682-449e-48fe-9833-9a96d158791e Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2016 third_quarter PHA Any legislation and regulation to the treatment of opioid abuse. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-10-07T14:06:54.913000-04:00
1873923 AMERICAN AMBULANCE ASSOCIATION 26bcdfbc-a317-4567-9c81-c36f272d5ddf Q3 AMERICAN AMBULANCE ASSOCIATION 56018 AMERICAN AMBULANCE ASSOCIATION 2016 third_quarter PHA Lobbied in support of the Protecting Patient Access to Emergency Medications Act (H.R. 4365, S. 2932) to ensure the continuity of standing orders for the administration of certain controlled substances by paramedics and EMTs to patients. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   300000 0 0 2016-10-07T16:12:35.500000-04:00
1874040 PARRY, ROMANI, DECONCINI & SYMMS 0b7a72b9-1df4-43a6-8783-d6e6e269163c Q3 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 18000   0 0 2016-10-08T12:18:07.800000-04:00
1874108 INDEPENDENT PHARMACY COOPERATIVE 7ab117e6-ff04-45fe-a9f8-9571f6ba53e6 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2016 third_quarter PHA H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. S.524 Comprehensive Addiction and Recovery Act of 2016. IPC is against as currently written. Actual Acquisition Cost (AAC) adoption with state Medicaid programs. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-10-09T16:24:39.720000-04:00
1874151 HANCE SCARBOROUGH d14a4b85-7364-45b2-a6c2-d841a2a78833 3T HANCE SCARBOROUGH 17443 ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS 2016 third_quarter PHA Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs. HOUSE OF REPRESENTATIVES,SENATE     0 1 2016-10-10T10:36:39.560000-04:00
1874571 ROCK & ASSOCIATES f70c170c-b906-4f17-bcf7-c2a5ed953865 Q3 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-10-11T02:47:12.383000-04:00
1874575 ROCK & ASSOCIATES b140c0d8-9c02-4ef4-b7e3-5d96d56b26d2 Q3 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-10-11T02:52:15.133000-04:00
1874581 ROCK & ASSOCIATES 706ed458-7389-4d3c-8a59-042e0dfb301b Q3 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-10-11T02:55:16.760000-04:00
1874584 ROCK & ASSOCIATES 514f70c4-e51e-44d1-8570-a270592984f0 Q3 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-10-11T02:57:18.263000-04:00
1874589 ROCK & ASSOCIATES 3af5d910-68a9-47f0-8496-0591913141a9 Q3 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-10-11T02:59:19.700000-04:00
1874592 ROCK & ASSOCIATES a2f0bc62-a7ae-4509-b770-4a8b8c8df3ab Q3 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2016 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2016-10-11T03:01:21.200000-04:00
1874637 MR. BRIAN KELLY b3042ccb-6dce-4b3b-85f0-3a9d11648ad6 Q3 MR. BRIAN KELLY 40024191 LUNDBECK PHARMACEUTICALS 2016 third_quarter PHA FDA Reform HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2016-10-11T10:08:06.227000-04:00
1874774 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM e2452ed8-6415-42c3-a264-2de027e4926a Q3 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2016 third_quarter PHA Any language supporting the expanded use of virtual care/telemedicine, including HR 2799 supporting changes in definitions to expand the use of telemedicine. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   28557 0 0 2016-10-11T11:52:30.400000-04:00
1875019 HOLLAND & KNIGHT LLP 3b2ae95c-54cb-4650-bf8e-c22ff2e3531d Q3 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2016 third_quarter PHA Advocating for policy to ensure patient access to pain relief. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-11T15:19:17.800000-04:00
1875028 HOLLAND & KNIGHT LLP cc96cfb9-b0e7-42e5-81e3-1d2c584170c5 Q3 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2016 third_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars. HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2016-10-11T15:25:21.837000-04:00
1875088 AMERICAN PHARMACISTS ASSOCIATION 475547b7-75cd-4d23-8f31-f7cbefbcdbef Q3 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2016 third_quarter PHA Reimbursement of Pharmacist Services (HR592, S314) Transitions of Care Risk Evaluation and Mitigation Services Track and Trace/Supply Chain Health Information Technology Immunizations Compounding Tele-medicine Quality Rating AMP FULs/MAC Pricing Biosimiliars/Biologic Products (S 2700) Drug Importation Generics Labeling Pharmacy Benefit Managers Preferred Pharmacy Network (HR793) Electronic Labeling 21st Century Cures (HR6, HR 350) Drug Disposal/Management Drug Prices Direct and Indirect Remuneration Fees (HR 5951, S 3308) Cody Miller Act (S 2214) Lab Developed Tests Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   30000 0 0 2016-10-11T16:31:18.867000-04:00
1875204 CONNECT 4 STRATEGIES, LLC 132c7d00-998a-4dc4-a133-2395f3511263 Q3 CONNECT 4 STRATEGIES, LLC 401103720 BIOMARIN PHARMACEUTICAL INC. 2016 third_quarter PHA Rare pediatric review voucher. S 1878 and HR 1537 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-10-11T20:49:32.220000-04:00
1875257 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY ab5ea350-583a-468b-86bc-e0d96f47b291 Q3 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 401097063 UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 2016 third_quarter PHA --340B Program Mega Guidance Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   6695 0 0 2016-10-12T10:08:05.457000-04:00
1875549 ARNALL GOLDEN GREGORY, LLP cbc0dff1-e931-4125-a78f-e2f7cc7ed9f2 Q3 ARNALL GOLDEN GREGORY, LLP 400713137 PHARMA AND BIOPHARMA OUTSOURCING ASSOCIATION 2016 third_quarter PHA FDA issues; Generic Drug Free User Act issues; small business relief legislation HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-10-12T14:00:01.390000-04:00
1875612 AMERICAN PHARMACISTS ASSOCIATION 084fd17f-132e-4b9a-a5b8-a8d931f23d21 3A AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2016 third_quarter PHA Reimbursement of Pharmacist Services - HR592/S314 Transitions of Care Risk Evaluation and Mitigation Services Track and Trace/Supply cChain Health Information Technology Immunizations Compounding Tele-Medicine Quality Rating AMP FULs/MAC P ricing Biosimiliars/Biologic Products (S 2700) Drug Importation Generics Labeling Pharmacy Benefit Managers Preferred Pharmacy Network (HR793) Electronic Labeling 21st Century Cures/Innovation Bills (HR6, HR 350) Drug Disposal/Management Drug Prices Direct and Indirect Remuneration Fees (HR 5951, S3308) Lab Developed Tests Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   30000 0 0 2016-10-12T14:25:28.557000-04:00
1875800 VAN FLEET ASSOCIATES db2b65a4-3471-421e-9a97-44d731b5c9e2 3A VAN FLEET ASSOCIATES 39781 INNOVATIVE BIODEFENSE 2016 third_quarter PHA Counter FDA warning letter. Food & Drug Administration (FDA)     0 0 2016-10-12T15:42:49.753000-04:00
1876254 THORSEN FRENCH ADVOCACY LLC 47719359-13ab-475b-a9a6-1ab03b1241c1 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 CARDINAL HEALTH, INC. 2016 third_quarter PHA Issues related to prescription drug abuse. Issues related to pharmaceutical market value. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-13T10:19:06.483000-04:00
1876274 THORSEN FRENCH ADVOCACY LLC b793e62a-7dbc-47ad-b6b5-ffca18179544 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2016 third_quarter PHA Issues related to pharmaceutical market value. Issues related to prescription drug abuse. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-13T10:30:26.420000-04:00
1876592 THORSEN FRENCH ADVOCACY LLC 006739fb-fcbe-42d3-99dd-5111cb858e36 Q3 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2016 third_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-10-13T13:00:32.527000-04:00
1876683 MERCURY PUBLIC AFFAIRS, LLC 711172e2-d0bf-4ed9-9b7a-3929baea9596 Q3 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2016 third_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2016-10-13T13:48:36.973000-04:00
1876703 KENT & O'CONNOR, INC. 8223d458-cc2e-4603-8fdd-7b2c240a94ba Q3 KENT & O'CONNOR, INC. 21426 INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION 2016 third_quarter PHA Legislation and regulations relating to drug and safety issues. Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection 20000   0 0 2016-10-13T13:55:50.747000-04:00
1876846 KATE MOSS 6ac47e33-a342-4250-b943-7fe8413199bd Q3 KATE MOSS 25988 CVS HEALTH 2016 third_quarter PHA Issues related to prescription drug abuse and drug supply chain safety. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-10-13T15:15:38.770000-04:00
1876970 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 1e87a48d-77a7-4ccc-9f48-fd31f75a9701 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2016 third_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Extended Producer Responsibility/Pharmaceutical Stewardship (Drug Take-Back) H.R. 4931 - Pharmaceutical Stewardship Act of 2016. Requires the Drug Enforcement Administration to establish and implement a national pharmaceutical stewardship program to collect and dispose of prescription medications; all sections. H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 (COARA). Amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize the Attorney General to make grants to assist State and local governments in addressing the national epidemic of opioid abuse, and for other purposes (all sections). S. 524 - Comprehensive Addiction and Recovery Act of 2016 (CARA; became P.L. 114-198 on 7/22/2016). Authorizes the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes (Section 201 - expands eligible uses of grant funds to include drug take-back efforts; Section 203 requires coordination among multiple government agencies to develop a prescription drug take-back program). Oral Contraceptives H.R. 5138 - Over-the-Counter Contraceptives Act of 2016. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-… Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   290000 0 0 2016-10-13T16:13:55.930000-04:00
1876980 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 29cde65d-9b23-4781-b997-ff2677fc9738 Q3 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2016 third_quarter PHA Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE,Veterans Affairs, Dept of (VA)   70000 0 0 2016-10-13T16:24:03.787000-04:00
1877009 ACADEMY OF MANAGED CARE PHARMACY 833f1032-a9c9-4aea-93d7-c54d7b63be73 Q3 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2016 third_quarter PHA Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. Comments to FDA on biosimilars labeling draft guidance advocating for changes to the biosimilarity statement and biosimilar product identification and naming sections. Comments to the FDA on PDUFA VI reauthorization. for its continued focus on patient safety and quality patient care. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records. Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   168000 0 0 2016-10-13T17:00:32.367000-04:00
1877170 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 60b6a3c7-9192-4b38-b5cf-0a6132a1dd3a Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2016 third_quarter PHA H.R. 244 - MAC Transparency Act of 2015; Congressional Oversight of 340 B Program; S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act; Issues related to FDA implementation of The Drug Quality and Security Act related to compounding; Issues Related to Direct and Indirect Renumeration (DIR) Fees; H.R. 5951/S. 3308 - Improving Transparency and Accuracy in Medicare Part D Spending Act Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE   335000 0 0 2016-10-14T09:26:17.153000-04:00
1877541 JOHNS HOPKINS UNIVERSITY 510fe923-8f5c-4e5e-9e28-8ddb2f22b05d Q3 JOHNS HOPKINS UNIVERSITY 20664 JOHNS HOPKINS UNIVERSITY 2016 third_quarter PHA Pharmaceutical drug prices Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   100000 0 0 2016-10-14T12:30:31.617000-04:00
1878931 MEHLMAN CONSULTING, INC. faa59872-596c-425f-8baf-54b91ce75d15 Q3 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2016 third_quarter PHA Issues related to transparency and competition in the prescription drug market. S.3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES). S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016 (FAIR). Food and Drug Administration Appropriations Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2016-10-17T11:32:41.330000-04:00
1878997 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 5eacbcd9-8701-4d15-9e5c-fd320d4d9c63 Q3 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2016 third_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising H.R. 4565, Responsibility in Drug Advertising Act of 2016, to prohibit for three years after FDA approval direct to consumer prescription drug advertising Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE   420000 0 0 2016-10-17T11:41:18.197000-04:00
1879019 MEHLMAN CONSULTING, INC. c3c38c65-790f-43de-8a5a-861e5042b20c Q3 MEHLMAN CONSULTING, INC. 284950 WALMART INC 2016 third_quarter PHA Implementation of Medicare Part D and the Affordable Care Act. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2016-10-17T11:43:27.557000-04:00
1879022 MEHLMAN CONSULTING, INC. 9274968e-383d-499e-b926-02c44bf1bded Q3 MEHLMAN CONSULTING, INC. 284950 VIRTUS PHARMACEUTICALS LLC 2016 third_quarter PHA Generic Drugs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-17T11:45:30.170000-04:00
1879066 WILLIAMS AND JENSEN, PLLC db20de44-8b17-43e1-a847-d3bb833bea68 3T WILLIAMS AND JENSEN, PLLC 41454 FAGRON NORTH AMERICA 2016 third_quarter PHA Issues related to Drug Quality and Security Act (DQSA) and pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 10000   0 1 2016-10-17T11:58:49.540000-04:00
1879349 CHAMBER HILL STRATEGIES ab3f09f7-8c56-4a9c-a7a9-26521009326d Q3 CHAMBER HILL STRATEGIES 400645947 AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) 2016 third_quarter PHA Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-17T13:38:47.083000-04:00
1879409 WALTER CONSULTING 30642ddd-8c4b-476c-8a44-e7dc21e44e1a Q3 WALTER CONSULTING 301697 AMERISOURCEBERGEN CORPORATION 2016 third_quarter PHA H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-10-17T13:52:19.127000-04:00
1879614 RED+BLUE STRATEGIES 3435f6f1-249c-48a7-a1fb-e7ee660b8b4b Q3 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2016 third_quarter PHA H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid funding and other prescription drug related issues. National Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs. Issues related to the pricing of prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-17T14:26:54.313000-04:00
1879669 RED+BLUE STRATEGIES 04a6d35d-4b18-4e77-8510-2369473e5b70 Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2016 third_quarter PHA H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies. The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-17T14:37:31.120000-04:00
1879780 RED+BLUE STRATEGIES 7996fd7d-2c67-4694-b644-9ce7bcc568bf Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2016 third_quarter PHA H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues, policies focused on antibiotic resistance and other public health related policies. S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction. S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program. H.R. 5054 - Agriculture Appropriations Bill for FY 2017 - Issues related to FDA treatment of antibiotics and compounding of certain pharmaceuticals. Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC. Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget. Supporting policies to maintain the integrity of laws regarding compounding of certain medications. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-17T14:54:37.977000-04:00
1879898 NORIDIAN MUTUAL INSURANCE COMPANY 68fbbb48-6d7a-4d9a-b74e-f0b9140edbd2 Q3 NORIDIAN MUTUAL INSURANCE COMPANY 6473 NORIDIAN MUTUAL INSURANCE COMPANY 2016 third_quarter PHA Opioid Education, Pharmaceutical cost containment HOUSE OF REPRESENTATIVES,SENATE     0 0 2016-10-17T15:16:47.467000-04:00
1879976 ACG ADVOCACY 3a085c09-85ae-4140-a5a6-6f51f429797d Q3 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2016 third_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-17T15:30:33.463000-04:00
1880119 EXPRESS SCRIPTS, INC. c8eb482b-233f-48ad-9385-e2f9e05ee3bc Q3 EXPRESS SCRIPTS, INC. 294416 EXPRESS SCRIPTS, INC. 2016 third_quarter PHA Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office   690000 0 0 2016-10-17T16:02:20.507000-04:00
1880265 MR. GALEN RESER 9bd6644a-92cd-466c-b8e0-b2f6556bd882 Q3 MR. GALEN RESER 401055978 PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) 2016 third_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-10-17T16:19:38.427000-04:00
1880356 MEHLMAN CONSULTING, INC. 31e08d6c-cfed-47ab-bae3-acdc6f190e78 Q3 MEHLMAN CONSULTING, INC. 284950 ASCENSION HEALTH ALLIANCE 2016 third_quarter PHA Prescription Drugs Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES) FAIR Drug Pricing Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-10-17T16:39:30.227000-04:00
1880700 EMPIRE CONSULTING GROUP ed881810-8108-4d57-b6b7-f2b8912605ce Q3 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2016 third_quarter PHA Issues relating to Medicare Parts D and D; prescription drug costs/pricing; legislation and issues relating to opioids; budget. HOUSE OF REPRESENTATIVES 40000   0 0 2016-10-17T21:33:54.513000-04:00
1880821 GREATER NEW YORK HOSPITAL ASSOCIATION b9e10b6e-11f5-4206-9151-a820748b5665 Q3 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2016 third_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases and support draft reform legislation; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment, oppose use of savings from home infusion payment reform for purposes other than creating a Medicare home infusion benefit; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments and Capitol Hill meetings on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed… Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   410000 0 0 2016-10-18T08:58:40.667000-04:00
1881033 BLUECROSS BLUESHIELD OF TENNESSEE 6a312c8d-010f-4ca4-8301-453b2eed09a4 Q3 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2016 third_quarter PHA General Pharmacy Issues (HR6/2713); opioid abuse (S524, HR953, HR2805, HR4499); specialty drug pricing Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2016-10-18T10:12:56.763000-04:00
1881104 RED+BLUE STRATEGIES cae75a8d-5a66-48d5-bc7b-b9404e9db24c Q3 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2016 third_quarter PHA H.R. 5327 - Continuing Appropriatins and Military Construction, VA and Related Agencies Appropriations Act of 2017 and Zika Response and Preparedness Act. Issues regarding the funding of opioid related programs. S. 524 - the Comprehensive Addition and Recovery Act- issues related to ensuring best prescribing practices for opioids in the country and solutions developed by BCBSMA to combat abuse. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-18T10:24:51.070000-04:00
1881168 RED+BLUE STRATEGIES 755b268c-7ecc-4fc1-9ea1-df7343f7a1c0 Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2016 third_quarter PHA H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars. Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-18T10:34:19.890000-04:00
1881350 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) f71f42e0-c671-47a5-a9ec-459d6b248190 Q3 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 400265214 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 2016 third_quarter PHA Issues related to pharmaceutical pricing and federal oversight by the FDA Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   198000 0 0 2016-10-18T10:59:57.647000-04:00
1881593 TODD STRATEGY GROUP 8a9c20db-1179-41e2-bd6e-4d3b258b5c20 Q3 TODD STRATEGY GROUP 401103321 BIOTECHNOLOGY INNOVATION ORGANIZATION 2016 third_quarter PHA Drug Pricing and Access. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-18T11:33:09.410000-04:00
1881604 TODD STRATEGY GROUP cad95db9-c2de-435e-95f4-926d02e11f91 Q3 TODD STRATEGY GROUP 401103321 CELGENE CORPORATION 2016 third_quarter PHA S.3056 - CREATES Act of 2016. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-10-18T11:35:16.633000-04:00
1881716 SAFEWAY INC. 373a9c2d-ad05-4992-88a1-281f3cd09cd4 Q3 SAFEWAY INC. 300173 SAFEWAY 2016 third_quarter PHA H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act, all provisions. H.R. 4909, FY 2017 National Defense Authorization Act, provisions related to TRICARE and pharmacy access. H.R. 953/S. 524, Comprehensive Addition and Recovery Act, provisions related to state prescription drug monitoring programs. H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, all provisions. H.R. 3250, DXM Abuse Prevention Act, provisions related to retail pharmacy. HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2016-10-18T11:53:16.210000-04:00
1881790 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 154908f0-94cb-44a4-bd02-fd0ded9da77b Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2016 third_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2016-10-18T12:01:55.530000-04:00
1881804 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 9c27e79a-87d3-4515-979a-70a1cadee1a7 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2016 third_quarter PHA HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2016-10-18T12:05:03.580000-04:00
1881807 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. cd1f1672-61fa-4558-ac49-a5a11f1cc54d Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2016 third_quarter PHA issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-18T12:05:06.173000-04:00
1881826 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 702e2f60-a412-4860-958c-6ad7f97e03c3 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2016 third_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2016-10-18T12:06:14.973000-04:00
1881947 THORN RUN PARTNERS 4d60f017-1cd2-4d3d-89fd-4b7f05eef1b2 Q3 THORN RUN PARTNERS 400534596 EXPRESS SCRIPTS, INC. 2016 third_quarter PHA H.R.244, MAC Transparency Act; pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. S.2943/H.R.4909, National Defense Authorization Act for Fiscal Year 2017; provision authorizing a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-18T12:28:31.257000-04:00
1882059 MCDERMOTT+ LLC 0cad3c00-4fc4-4d59-ac93-712b8d26baab Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2016 third_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-10-18T12:48:37.877000-04:00
1882136 MASSACHUSETTS MEDICAL SOCIETY 11325f1e-90e6-426a-97a8-1d7c6a6af5fc Q3 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2016 third_quarter PHA Prescription Drug Pricing - no specific bill Direct to Consumer Advertising - no specific bill Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA)   50000 0 0 2016-10-18T13:02:14.550000-04:00
1882188 CLOAKROOM ADVISORS LLC 5b7c304f-8538-4050-b0d9-0f8cdfa9ae37 3T CLOAKROOM ADVISORS LLC 401103204 LINDEN CARE LLC 2016 third_quarter PHA Congressional delegation outreach and education on issues related to speciality pharmacies HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2016-10-18T13:09:38.417000-04:00
1882207 CLOAKROOM ADVISORS LLC a8c48d5c-561b-4b89-9c6a-55ca4160c17b Q3 CLOAKROOM ADVISORS LLC 401103204 CARD & ASSOCIATES ON BEHALF OF AMERICAN'S FOR PRESCRIPTION DRUG FAIRNESS 2016 third_quarter PHA Advocate for protection of 340B drug pricing program and support 340B program integrity and compliance by covered entities and pharmacies. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-10-18T13:14:53.547000-04:00
1882452 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC c9a7a449-0ce3-4b21-8055-b73fd0ca5f8f Q3 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 17966 ELI LILLY AND COMPANY 2016 third_quarter PHA Policy issues relating to prescription drug prices. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-18T13:43:12.447000-04:00
1882693 ALKERMES, INC. 6028fe3a-0e5f-4fe2-84a1-ef66a9588189 Q3 ALKERMES, INC. 400458235 ALKERMES, INC. 2016 third_quarter PHA Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   1150000 0 0 2016-10-18T14:23:51.233000-04:00
1882948 BLUESTONE STRATEGIES, LLC 48a657be-d4f9-4043-824a-acb87dc73922 Q3 BLUESTONE STRATEGIES, LLC 400658980 AMERICA'S HEALTH INSURANCE PLANS (AHIP) 2016 third_quarter PHA Specialty Drugs and Prescription Drug Pricing HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-18T14:48:23.567000-04:00
1883231 ARNOLD & PORTER KAYE SCHOLER LLP 086e2709-0b33-4ed4-839e-ef342eba7686 Q3 ARNOLD & PORTER KAYE SCHOLER LLP 4301 INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS 2016 third_quarter PHA Issues related to the regulation of pharmacy compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-18T15:14:20.260000-04:00
1883266 NOVO NORDISK INC. 0f41faea-12e8-471f-811a-22cf0e70e4bb Q3 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2016 third_quarter PHA P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Indian Health Service,Labor, Dept of (DOL),Natl Institutes of Health (NIH),SENATE,Treasury, Dept of   590000 0 0 2016-10-18T15:19:41.093000-04:00
1883296 BLUESTONE STRATEGIES, LLC 57d151cb-03d7-4af5-87f7-9aeb168768fa Q3 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2016 third_quarter PHA Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2016-10-18T15:25:03.397000-04:00
1883306 AMERICAN VETERINARY MEDICAL ASSOCIATION 59f6bf25-b473-4cb6-a3a2-8a4a2a293e15 Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2016 third_quarter PHA S. 1200/H.R. 3174 Fairness to Pet Owners Act Veterinary Compounding Legislation Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230 Discussions with DEA regarding use of controlled substances by veterinary practitioners HOUSE OF REPRESENTATIVES,SENATE   200000 0 0 2016-10-18T15:27:10.867000-04:00
1883340 COVINGTON & BURLING LLP adbd6d22-4a46-4dee-afa8-f3be20d338d1 Q3 COVINGTON & BURLING LLP 11195 CELGENE CORPORATION 2016 third_quarter PHA Opposing the CREATES Act, S. 3056 HOUSE OF REPRESENTATIVES,SENATE 250000   0 0 2016-10-18T15:32:35.247000-04:00
1883355 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION a3ecba90-6299-4506-8c1a-664aa8302f19 Q3 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2016 third_quarter PHA Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2: Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244: The MAC Transparency Act H.R.793S1190: The Ensuring Seniors Access to Local Pharmacies Act H.R.1021: The Protecting the Integrity of Medicare Act H.R.1600: The Patient Access to Treatments Act H.R.804: The Access to Medicare Data Act H.R.2298: The Medicare Drug Abuse Prevention Act H.R.6: 21st Century Cures Act H.R. 1735/S.1376: The National Defense Authorization Act - Provisions related to TRICARE pharmacy H.R. 4062: Protecting Seniors Access to Proper Care Act H.R. 5951/ S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),General Services Administration (GSA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   643584 0 0 2016-10-18T15:33:46.187000-04:00
1883598 ISEMAN & ASSOCIATES LLC 01cb01c1-3cb9-40a8-8126-67c0c6e7b8e7 Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2016 third_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-10-18T16:17:17.613000-04:00
1884231 CROSSROADS STRATEGIES, LLC e54339c3-8af4-4c2d-ad83-82fb86878664 Q3 CROSSROADS STRATEGIES, LLC 400531586 EMD SERONO, INC. 2016 third_quarter PHA General pharmaceutical coverage and reimbursement issues. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-18T18:02:54.537000-04:00
1884507 CAPITOL COUNSEL LLC 77e12926-5bfa-42dd-8da4-3bd708726b9c Q3 CAPITOL COUNSEL LLC 313715 AMERICAN HEALTH CARE ASSOCIATION 2016 third_quarter PHA S.1560: Nursing Home Resident Pain Relief Act of 2011. S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012. S.621: Safe Prescribing Act. Continued monitoring of Nurse Agent and Drug disposal issue HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2016-10-18T22:07:05.550000-04:00
1884870 RAMPY NORTHRUP LLC ea46367c-9c88-42c4-b5b0-26db67cd1581 Q3 RAMPY NORTHRUP LLC 401103289 ACADEMY OF MANAGED CARE PHARMACY 2016 third_quarter PHA Dissemination of pharmacoeconomic information. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-19T09:10:02.387000-04:00
1884946 FLYNN & ASSOCIATES, INC. 72dfe6d6-bd06-4da9-bd8e-1a0462414b6b Q3 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2016 third_quarter PHA Medicare Part-D rebates Trade agreements Patent reform issues Medicare Part-B Doctor reimbursement regulations HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2016-10-19T09:30:43.657000-04:00
1885002 RUBICON ADVISORS, LLC ebac689d-1bc7-43a4-b092-c450198e07b2 Q3 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2016 third_quarter PHA 21st Century Cures Act HOUSE OF REPRESENTATIVES,SENATE 105000   0 0 2016-10-19T09:56:29.897000-04:00
1885118 RUBICON ADVISORS, LLC dd1342f7-0b39-415a-91f4-6b326fc267cd 3T RUBICON ADVISORS, LLC 315091 OFFICE OF GOVERNOR NATHAN DEAL 2016 third_quarter PHA Pharmaceuticals HR 707, Restoration of America's Wire Act HOUSE OF REPRESENTATIVES,SENATE 43750   0 1 2016-10-19T10:09:32.190000-04:00
1885124 RUBICON ADVISORS, LLC e00b1fc9-fe1d-4549-8534-f36775311531 Q3 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2016 third_quarter PHA Pharmaceuticals HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2016-10-19T10:10:37.757000-04:00
1885137 RUBICON ADVISORS, LLC 91fbeea6-80f5-4059-86ab-db2017fdd42a Q3 RUBICON ADVISORS, LLC 315091 ALLIANCE TO PREVENT THE ABUSE OF MEDICINES 2016 third_quarter PHA Prescription drug abuse policy HOUSE OF REPRESENTATIVES,SENATE 52500   0 0 2016-10-19T10:10:48.100000-04:00
1885141 RUBICON ADVISORS, LLC eb095205-ac0a-4d9d-9db4-5f84bd5c0747 Q3 RUBICON ADVISORS, LLC 315091 COLLEGE OF AMERICAN PATHOLOGISTS 2016 third_quarter PHA Physician Payment Rates, Electronic Health Records Incentives program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2016-10-19T10:11:54.130000-04:00
1885154 RUBICON ADVISORS, LLC 167a07ac-8ecc-450e-ba2c-393c27a80549 Q3 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2016 third_quarter PHA Food and Drug Administration, Generic Drug User Fees, NHI, DEA Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2016-10-19T10:12:59.147000-04:00
1885446 THE INGRAM GROUP LLC 734cf5f7-d90a-41cc-88c7-2bba973da928 Q3 THE INGRAM GROUP LLC 400577737 ELI LILLY AND COMPANY 2016 third_quarter PHA S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015. H.R.6, 21st Century Cures Act. General issues related to the biopharmaceutical and pharmaceutical industries. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2016-10-19T10:45:02.753000-04:00
1885500 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS a738fdf2-4e25-42dd-9f55-bc78a2463b32 Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2016 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   230000 0 0 2016-10-19T10:50:38.117000-04:00
1885523 THE D MAJOR GROUP 48baae31-9fe3-49ce-abea-ee78ed055540 Q3 THE D MAJOR GROUP 401103162 CVS CAREMARK 2016 third_quarter PHA Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 34500   0 0 2016-10-19T10:52:54.090000-04:00
1885584 FORBES-TATE 5b737898-6d5d-4be6-baf5-1092ec5a0cc9 Q3 FORBES-TATE 400976792 PHRMA 2016 third_quarter PHA Issues related to Medicare Part D; issues related to the drug industry, issues related to comparative effectiveness; issues related to follow-on biologics; issues related to the Independent Payment Advisory Board; issues related to patent reform; issues related to ASP+6 and Part B rule; issues related to PCORI; issues related to pharmaceutical drug safety track and trace program legislation; issues related to low income subsidies; issues related to the Vice President's National Cancer Moonshot Initiative. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2016-10-19T10:57:33.233000-04:00
1885816 PRIME THERAPEUTICS 35f3af34-1b30-484e-b075-2e9bf50fa79f Q3 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2016 third_quarter PHA S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2016-10-19T11:18:47.580000-04:00
1886085 UNIVERSITY OF IOWA 81b2f2a6-4529-46b9-b907-5f216f6d8bfb Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2016 third_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals 340B Drug Pricing guidelines Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   86662 0 0 2016-10-19T11:40:55.943000-04:00
1886353 DENTONS US LLP 17f9803b-b6a3-4bf8-83c2-ed7ad254b284 Q3 DENTONS US LLP 36105 PURDUE PHARMA 2016 third_quarter PHA U.S. and Canadian regulatory policies regarding prescription drug abuse       0 0 2016-10-19T12:09:19.533000-04:00
1886538 ELI LILLY AND COMPANY 0381ff45-a6fb-407a-a20b-75d2556ecb8b Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2016 third_quarter PHA Hospital discounts; 340B Program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2100000 0 0 2016-10-19T12:29:11.300000-04:00
1886692 DENTONS US LLP 035ef305-6586-411b-8982-ccf7572eb61c Q3 DENTONS US LLP 36105 AMERISOURCEBERGEN 2016 third_quarter PHA Pharmaceutical pedigree anti-counterfeiting issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2016-10-19T12:50:41.913000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2661.78ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API